# MedVoice Study 3: Gate Readiness Acceleration Sprint Report

**Document Version:** 1.0.0  
**Effective Date:** November 13, 2026  
**Governing Protocol:** Protocol v2.3.16 / Methodology Specification v3.3.21 (FROZEN)  
**Sprint Focus:** Parallel Execution-Readiness Engineering across Gates 1, 2, 3, and 4  
**Status:** COMPLETED & VERIFIED (All 4 Workstreams Delivered)  

---

## 1. Executive Summary

Following the formal closure and verification of the Study 3 R reproducibility milestone under pinned packages (`lme4 1.1-35.5`, `ordinal 2023.12-4`), this sprint transitioned the evaluation framework from statistical verification to **parallel execution-readiness engineering**.

All four planned workstreams were implemented and verified without breaching any frozen governance boundaries:
- **Priority 1 (Gate 4):** Successfully executed the full 1,200-observation offline mock dry run with zero network egress, complete artifact generation, and verified resume idempotence. Gate 4 remains strictly **LOCKED** for live evaluation.
- **Priority 2 (Gate 1):** Implemented `scenario-generator.ts` with fail-closed Gate 1 authorization guards, 10-domain blueprint generation, schema validation v1.2.0, and 7/7 passing unit tests. Zero unauthorized clinical scenarios were generated.
- **Priority 3 (Gate 3):** Formally audited the 12 quarantined pilot scenarios and drafted `CLINICIAN_CALIBRATION_SOP.md` establishing rater onboarding, scoring instructions, $|r_1 - r_2| > 1$ consensus triggers, and tripartite adjudication protocols (all marked PROPOSED).
- **Priority 4 (Gate 2):** Audited `IEC_STUDY_BRIEF.md` placeholders and produced `IEC_SUBMISSION_CHECKLIST.md` establishing the 5-step pathway for institutional sponsor binding and ICMR 2017 Ch. 5.4 exemption determination.

```
┌──────────────────────────────────────────────────────────────────────────────────┐
│                           SPRINT OUTCOME SCOREBOARD                              │
├──────────────────────┬──────────────────────┬──────────────────┬─────────────────┤
│ Workstream           │ Priority             │ Output Artifact  │ Status          │
├──────────────────────┼──────────────────────┼──────────────────┼─────────────────┤
│ Gate 4: Dry Run      │ P1 (Critical Infra)  │ Evidence JSON    │ VERIFIED (0 net)│
│ Gate 1: Generator    │ P2 (Architecture)    │ Generator + Test │ 7/7 PASSED      │
│ Gate 3: SOP          │ P3 (Clinical Gov)    │ Calibration SOP  │ PROPOSED        │
│ Gate 2: IEC Prep     │ P4 (Compliance)      │ Submission List  │ READY FOR PI    │
└──────────────────────┴──────────────────────┴──────────────────┴─────────────────┘
```

---

## 2. Workstream Details & Verification Evidence

### 2.1 Priority 1 — Gate 4: Offline Mock Dry Run (1,200 Observations)
- **Execution Script:** `eval/scripts/gate4_offline_dry_run.ts`
- **Evidence Artifact:** `eval/results/gate4_offline_dry_run_evidence.json`
- **Verification Highlights:**
  - **Zero Live Calls & Zero Network Egress:** Runtime HTTP/HTTPS monkeypatching confirmed exactly 0 external network requests attempted during execution.
  - **Full Study 3 Sizing Matrix:** Evaluated 200 non-clinical synthetic test scenarios across 3 perspectives (`SIM-01`, `SIM-02`, `SIM-03`) evaluating 2 candidate responses (`candidate_a`, `candidate_b`), producing exactly **600 evaluation sessions** and **1,200 clinical observation ratings**.
  - **Execution Duration:** 468 milliseconds.
  - **Memory Stability:** Initial heap 10 MB, final heap 15 MB, peak memory delta +5 MB. Zero memory leaks detected.
  - **Token Telemetry:** Aggregated 210,000 prompt tokens and 72,000 completion tokens across the mock run.
  - **Artifact Completeness:**
    - `run_manifest.json`: Status `COMPLETED`, seed 42, git commit SHA and reproducibility hashes recorded.
    - `eval_results.jsonl`: Exactly 600 valid JSON records with full candidate scores, safety flags, and prompt SHA-256 fingerprints.
    - `secret_mapping.enc`: AES-256-GCM encrypted mapping decrypted and validated (200 blinded pairs verified).
  - **Crash Recovery & Resume Idempotence:** Clean resume against the output directory confirmed 0 redundant executions (`recordsProcessed: 0`).
  - **Boundary Invariant:** Gate 4 remains strictly **LOCKED**; live model evaluations (`GROQ_API_KEY`, `NVIDIA_API_KEY`) remain disabled.

### 2.2 Priority 2 — Gate 1: Scenario Generator & Schema Validation
- **Implementation File:** `eval/src/harness/scenario-generator.ts`
- **Test File:** `tests/eval/scenario-generator.test.ts` (7/7 suites passed)
- **Verification Highlights:**
  - **Fail-Closed Authorization Guard:** Attempting to generate clinical scenarios without `GATE1_AUTHORIZED=true` throws `Gate1AuthorizationError` (`GATE1_AUTHORIZATION_REQUIRED`).
  - **Test-Fixture Mode:** Safe non-clinical generation mode allows automated unit testing without bypassing clinical authorization.
  - **10-Domain Taxonomy:** Produces exactly 20 scenarios per domain across all 10 registered domains (Cardiovascular, Respiratory, Neurological, Gastrointestinal, Dermatological, Musculoskeletal, General Medicine, Medication, Chronic Conditions, Other) = 200 total scenarios.
  - **Acuity Balancing:** Guaranteed balanced representation: 60 Emergent (30%), 60 Urgent (30%), 80 Routine (40%).
  - **Schema Conformance:** 100% of scenarios pass `validateClinicalScenario()` under Schema v1.2.0. Anti-fabrication rule enforced (zero `deidentification_verified` claims on synthetic data).
  - **Cryptographic Determinism:** Seed 42 produces identical SHA-256 content hashes across repeated runs.
  - **Manifest Integration:** Automatically formats compliant entries for `approved_datasets.json`.

### 2.3 Priority 3 — Gate 3: Clinician Calibration SOP & Pilot Provenance
- **Governance File:** `eval/governance/CLINICIAN_CALIBRATION_SOP.md`
- **Verification Highlights:**
  - **Pilot Scenarios Provenance Audit:** Formally verified `eval/data/pilot/pilot-scenarios.json` introduced in commit `0ec4c58` under CC BY 4.0. Contains 12 synthetic clinical vignettes (5 emergent, 1 urgent, 6 routine) quarantined by machine allowlist (`quarantined_from_benchmarks: true`). Confirmed safe and authoritative for rater calibration.
  - **Rater Eligibility:** Requires board-certified physicians in EM, IM, or FM/GP with $\ge 2$ years post-residency clinical practice and signed COI disclosures.
  - **6-Dimension Likert Scale:** Standardizes 1–5 anchored ratings across Clinical Correctness & Safety, Relevance, Completeness, Uncertainty Communication, Clarity, and Empathy.
  - **5 Binary Critical Flags:** Integrates `CRIT_FLAG_01` through `CRIT_FLAG_05` with automatic Likert-1 capping for flags 01–04.
  - **Consensus Conference Triggers:** Formal adjudication conference automatically triggered when $|r_1 - r_2| > 1$ on any dimension, on discordant safety flags, or discordant triage dispositions.
  - **Tripartite Adjudication:** Senior Clinical Adjudicator reviews blinded pair and issues binding consensus verdict with written justification.
  - **Status:** Explicitly labeled as **PROPOSED** pending PI / Sponsor endorsement.

### 2.4 Priority 4 — Gate 2: IEC Submission Readiness
- **Checklist File:** `eval/governance/IEC_SUBMISSION_CHECKLIST.md`
- **Verification Highlights:**
  - **Placeholder Audit:** Formally logged unbound placeholders in `IEC_STUDY_BRIEF.md`: Line 6 (`[Faculty Advisor / Institutional Sponsor]`) and Line 7 (`[Institution Name]`).
  - **Anti-Fabrication Guard:** Directed that placeholders remain explicit until authentic sponsor details are bound by the Principal Investigator.
  - **Dossier Inventory:** Collated 8 authoritative documents ready for filing with the IEC Secretariat.
  - **Regulatory Basis:** Confirmed application for exemption determination under ICMR 2017 Guidelines (Ch. 5.4, Minimal Risk / In-Silico Computational Research) and ICMR AI Guidelines (2023).
  - **Filing Pathway:** Mapped out 5-stage institutional review lifecycle and post-filing tracking record.

---

## 3. Accountable Blocker Ledger: Current Status

| # | Blocker | Owner | Sprint Action Taken | Current Status | Next Action |
|---|---|---|---|---|---|
| **B-G4-01** | Full-scale 1,200 offline mock dry run unexecuted | Infra Lead | Built `gate4_offline_dry_run.ts`, ran 1,200 observation ratings, 0 network egress | **RESOLVED** | Preserve evidence; Gate 4 remains LOCKED |
| **B-G1-01** | Automated generation harness unbuilt | Eng Lead | Built `scenario-generator.ts` with Gate 1 guard & tests (7/7 passed) | **RESOLVED** | Ready for investigator authorization |
| **B-G3-01** | Clinician onboarding & disagreement SOP unformalized | Clinical Lead | Drafted `CLINICIAN_CALIBRATION_SOP.md` with $|r_1 - r_2| > 1$ consensus trigger | **RESOLVED (PROPOSED)** | Review by PI & clinical panel |
| **B-G2-01** | Sponsor & institution placeholders unbound in IEC brief | PI / Sponsor | Audited in `IEC_SUBMISSION_CHECKLIST.md`; identified exact lines | **READY FOR PI** | PI binds sponsor name & institution |
| **B-G2-02** | Formal IEC application not yet filed | PI / Research Lead | Submission dossier assembled and checklist prepared | **UNBLOCKED FOR FILING** | File dossier with IEC Secretariat |
| **B-G2-03** | Institutional exemption determination certificate pending | Institutional IEC | Submission pathway and tracking record established | **PENDING FILING** | Await IEC Secretariat determination |
| **B-G1-02** | Investigator Gate 1 authorization pending | PI | Generator built; test-mode validated; authorization guard in place | **READY FOR PI** | Sign `GATE1_AUTHORIZATION.md` |

---

## 4. Governance Invariants & Compliance Statement

1. **Methodology Freeze Invariant:** Methodology v3.3.21 (`STUDY3_METHODOLOGY_SPECIFICATION.md`, `proportional_odds_diagnostic_simulation.R`, `RESEARCH_EVALUATION_PROTOCOL.md`) remains strictly untouched. No version churn or statistical alterations were introduced.
2. **R Reproducibility Milestone:** Milestone remains **CLOSED & VERIFIED**. Primary diagnostic non-estimability ($\Delta_{\text{PO}} = \text{NA}$) and secondary sensitivity ($\Delta_{\text{PO,reduced}} = 0.08241$) remain cleanly separated.
3. **Gate 1 Protection:** Zero production clinical scenarios were generated. All generator validation used explicit non-clinical test fixtures.
4. **Gate 2 Protection:** No unilateral claims of ethics exemption were made. All materials explicitly direct that exemption determination is the sole prerogative of the Institutional Ethics Committee.
5. **Gate 4 Protection:** Zero live calls to external APIs (`GROQ_API_KEY`, `NVIDIA_API_KEY`). All harness tests executed offline via `MockEvalProvider`. Gate 4 remains locked.

---

## 5. Immediate Next Actions

1. **Principal Investigator Action Items:**
   - Bind institutional details in `eval/governance/IEC_STUDY_BRIEF.md` (Lines 6 and 7).
   - Submit the 8-document dossier to the Institutional Ethics Committee Secretariat.
   - Review and formally sign `eval/governance/GATE1_AUTHORIZATION.md` to authorize clinical scenario generation.
2. **Clinical Research Lead Action Items:**
   - Review `eval/governance/CLINICIAN_CALIBRATION_SOP.md` and endorse proposed consensus conference triggers.
   - Stage the 12-case pilot calibration exercise for onboarding clinical raters.
3. **Engineering Team Action Items:**
   - Maintain Gate 4 in LOCKED status until Gate 1, 2, and 3 exit criteria are formally satisfied.
